| scholarly article | Q13442814 |
| P2093 | author name string | Bernard Portha | |
| Cécile Tourrel-Cuzin | |||
| Jamileh Movassat | |||
| P2860 | cites work | Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells | Q24535041 |
| Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line | Q24609542 | ||
| Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin | Q24642412 | ||
| Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells. | Q27863757 | ||
| cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells | Q27863919 | ||
| Functional interaction of the active zone proteins Munc13-1 and RIM1 in synaptic vesicle priming | Q28188061 | ||
| Targeted protein kinase A and PP-2B regulate insulin secretion through reversible phosphorylation | Q28200169 | ||
| The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth | Q28508976 | ||
| cAMP-GEFII is a direct target of cAMP in regulated exocytosis | Q28512994 | ||
| Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
| Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion | Q28575529 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Cross-talk between bone morphogenetic protein and transforming growth factor-beta signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells | Q28580123 | ||
| Beta-adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15 | Q28582314 | ||
| Control of insulin mRNA stability in rat pancreatic islets. Regulatory role of a 3'-untranslated region pyrimidine-rich sequence | Q28583369 | ||
| Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis | Q28586557 | ||
| Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP | Q22008544 | ||
| A family of cAMP-binding proteins that directly activate Rap1 | Q22008551 | ||
| Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors | Q24301709 | ||
| Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation | Q24307581 | ||
| A novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events | Q24324609 | ||
| A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice | Q51465533 | ||
| Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes | Q51746108 | ||
| Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans | Q53595650 | ||
| Effects of exendin-4 on islets from type 2 diabetes patients | Q57503692 | ||
| Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells | Q58088431 | ||
| GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts | Q60192351 | ||
| Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide | Q61836852 | ||
| Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells | Q73025342 | ||
| Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells | Q73224788 | ||
| Successful islet transplantation for patients with diabetes--fact or fantasy? | Q74055487 | ||
| GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress | Q79329446 | ||
| Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies | Q80076302 | ||
| Synergistic endocrine induction by GLP-1 and TGF-beta in the developing pancreas | Q80385788 | ||
| Interaction between Munc13-1 and RIM is critical for glucagon-like peptide-1 mediated rescue of exocytotic defects in Munc13-1 deficient pancreatic beta-cells | Q80636222 | ||
| Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells | Q80731025 | ||
| Exenatide and rare adverse events | Q94699384 | ||
| CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion | Q47994267 | ||
| Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. | Q42506332 | ||
| Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. | Q42520650 | ||
| Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells | Q42526631 | ||
| Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). | Q42574446 | ||
| Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice | Q43064614 | ||
| Decrease in {beta}-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of Exendin-4. | Q43089888 | ||
| Neonatal growth and regeneration of beta-cells are regulated by the Wnt/beta-catenin signaling in normal and diabetic rats. | Q43240236 | ||
| Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas | Q43276184 | ||
| Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism | Q43584830 | ||
| Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose | Q44083693 | ||
| Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice | Q44145661 | ||
| Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. | Q44193794 | ||
| cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets | Q44230933 | ||
| Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. | Q44328972 | ||
| Phosphorylation of RIM1α by PKA Triggers Presynaptic Long-Term Potentiation at Cerebellar Parallel Fiber Synapses | Q44609962 | ||
| Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. | Q44953902 | ||
| beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. | Q45242112 | ||
| A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth | Q46099186 | ||
| Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes | Q46122819 | ||
| Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. | Q46589919 | ||
| Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca2+ signal that is essential for insulin secretion in mouse pancreatic islets | Q46815586 | ||
| Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. | Q46949525 | ||
| Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas | Q47234077 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes | Q30440311 | ||
| Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance | Q33320681 | ||
| Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression | Q33796119 | ||
| Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. | Q34518622 | ||
| Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis | Q34530843 | ||
| Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element | Q34610365 | ||
| The role of incretins in glucose homeostasis and diabetes treatment | Q34901533 | ||
| Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). | Q35037304 | ||
| GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. | Q35098054 | ||
| Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system | Q35714885 | ||
| Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. | Q36288742 | ||
| Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells | Q36638807 | ||
| Anchoring of protein kinase A facilitates hormone-mediated insulin secretion | Q36834213 | ||
| Expression of the GLP-1 receptor in mouse, rat, and human pancreas | Q36838681 | ||
| Islet inflammation in type 2 diabetes: from metabolic stress to therapy. | Q37069944 | ||
| Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins | Q37091579 | ||
| Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation | Q37105326 | ||
| Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats | Q37176157 | ||
| The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? | Q37221610 | ||
| Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. | Q37248160 | ||
| Pancreatic duct replication is increased with obesity and type 2 diabetes in humans | Q37463887 | ||
| Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. | Q38296273 | ||
| cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells | Q38316164 | ||
| The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 | ||
| Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients | Q39679544 | ||
| Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells | Q39762883 | ||
| cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. | Q39895683 | ||
| Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway | Q40016200 | ||
| Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element | Q40307750 | ||
| Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. | Q40307766 | ||
| Involvement of PDX-1 in activation of human insulin gene transcription | Q40320021 | ||
| Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis | Q40488471 | ||
| Glucagon-like peptide-1 prevents beta cell glucolipotoxicity | Q40565084 | ||
| Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. | Q40625087 | ||
| Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor | Q40681109 | ||
| Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism | Q40708328 | ||
| Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells | Q40710884 | ||
| Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. | Q40731281 | ||
| Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation | Q40778317 | ||
| Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells | Q40814732 | ||
| IPF1, a homeodomain-containing transactivator of the insulin gene | Q40874284 | ||
| Glucagon-like peptide-1 does not mediate amylase release from AR42J cells | Q40921996 | ||
| Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. | Q41710424 | ||
| Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies | Q42448737 | ||
| cAMP-secretion coupling is impaired in diabetic GK/Par rat β-cells: a defect counteracted by GLP-1 | Q42491408 | ||
| Interplay of nutrients and hormones in the regulation of insulin release | Q42503141 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreas | Q9618 |
| type-1 diabetes | Q124407 | ||
| membrane protein | Q423042 | ||
| cell | Q7868 | ||
| signal transduction | Q828130 | ||
| cell surface receptor | Q2476074 | ||
| type 2 diabetes | Q3025883 | ||
| endocrine system | Q11078 | ||
| insulin-secreting cells | Q70229258 | ||
| human digestive system | Q9649 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 376509 | |
| P577 | publication date | 2011-05-22 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Experimental Diabetes Research | Q26842719 |
| P1476 | title | Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass | |
| P478 | volume | 2011 |
| Q34776341 | A novel strategy to increase the proliferative potential of adult human β-cells while maintaining their differentiated phenotype. |
| Q38053516 | An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease |
| Q34418605 | Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and Type 2 diabetes |
| Q38165184 | Diabetes and beta cell function: from mechanisms to evaluation and clinical implications |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q43046013 | Effect of mesenchymal stem cells transplantation on glycaemic profile & their localization in streptozotocin induced diabetic Wistar rats |
| Q40998901 | Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial |
| Q38984636 | Exploring the role of the HNF-1αG319S polymorphism in β cell failure and youth-onset type 2 diabetes: Lessons from MODY and Hnf-1α-deficient animal models |
| Q35920772 | Extending the Reach of Exendin-4: New Pathways in the Control of Body Weight and Glucose Homeostasis |
| Q38543982 | Food protein-derived bioactive peptides in management of type 2 diabetes |
| Q53147269 | GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn’s disease |
| Q38134115 | Glucagon-like peptide-1: modulator of β-cell dysfunction and death |
| Q52780711 | Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice |
| Q34699191 | Incretin-based therapies in prediabetes: Current evidence and future perspectives |
| Q38225693 | Incretins: their physiology and application in the treatment of diabetes mellitus. |
| Q51245616 | Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis. |
| Q37180829 | Mechanisms of current therapies for diabetes mellitus type 2 |
| Q51107548 | Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB. |
| Q27023585 | Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q91742866 | Recent advances in understanding the role of glucagon-like peptide 1 |
| Q24563430 | Regulation of glucose homeostasis by GLP-1 |
| Q38057350 | Review article: a comparison of glucagon‐like peptides 1 and 2 |
| Q39432694 | Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action |
| Q37398362 | Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with 99mTc-DTPA-glipizide |
| Q41662753 | The beneficial effect of growth hormone treatment on islet mass in streptozotocin-treated mice |
Search more.